Physiologically Based Pharmacokinetic Modeling of Metformin in Children and Adolescents With Obesity

• Published in: Journal of clinical pharmacology Vol. 62; no. 8; pp. 960 - 969
• Main Authors: Ford, Jennifer Lynn, Gerhart, Jacqueline G., Edginton, Andrea N., Yanovski, Jack A., Hon, Yuen Yi, Gonzalez, Daniel
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01-08-2022
• Subjects: Adolescent; Adolescents; Adult; Antidiabetics; Body weight; Body weight loss; Child; Children; Humans; Metformin; Metformin - pharmacokinetics; Models, Biological; Obesity; Obesity, Morbid; Overweight; PBPK modeling; Pediatric Obesity; Pediatrics; Pharmacokinetics; Teenagers; Weight control; pharmacokinetics; metformin; adolescents; children; PBPK modeling; obesity
• ISSN: 0091-2700; 1552-4604
• DOI: 10.1002/jcph.2034

Childhood obesity continues to rise in the United States and, with it, the off‐label use of metformin for weight loss. The influence of age and obesity on the drug's disposition and exposure has not previously been studied using a mechanistic framework. Here, an adult physiologically based pharmacokinetic (PBPK) model of metformin was scaled to pediatric populations without obesity, with overweight/obesity, and with severe obesity; a published virtual population of children and adolescents with obesity was leveraged during model evaluation. When the pediatric model was simulated in groups aged 10 to 18 years, oral clearance following 1000 mg of metformin was higher (≈1200 mL/min) in those with obesity and severe obesity compared to the groups without and with overweight (≈1000 mL/min). In addition, simulated area under the concentration‐time curve in older children and adolescents with obesity and severe obesity was comparable to that in adults with a similar dose‐exposure relationship. Overall, simulations using the pediatric PBPK model support the use of adult doses of metformin in older children and adolescents with obesity. Moreover, the virtual population of children and adolescents with obesity offers a valuable tool to facilitate development of pediatric PBPK models for studying populations with obesity and, in turn, contribute information to inform drug labeling in this special population.